Synopsis
Synopsis
0
CEP/COS
0
VMF
0
Listed Dossiers
0
FDF
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. (r)-3-((1-methyl-2-pyrrolidinyl)methyl)-5-(2-(phenylsulfonyl)ethyl)-1h-indole
2. (r)-3-((1-methyl-2-pyrrolidinyl)methyl)-5-(2-(phenylsulfonyl)ethyl)-1h-indole Monohydrobromide
3. 3-(1-methyl-2-pyrrolidinylmethyl)-5-(2-(phenylsulfonyl)ethyl)-1h-indole Hydrobromide
4. Eletriptan
5. Relpax
6. Uk 166,044
7. Uk 166044
8. Uk-116,044-04
9. Uk-116044-04
10. Uk-166,044
11. Uk-166044
1. 177834-92-3
2. Eletriptan Hbr
3. Relpax
4. Eletriptan Hydrobromide [usan]
5. Eletriptan (hydrobromide)
6. (r)-3-((1-methylpyrrolidin-2-yl)methyl)-5-(2-(phenylsulfonyl)ethyl)-1h-indole Hydrobromide
7. Eletriptan Monohydrobromide
8. Uk 116044-04
9. Chebi:61176
10. M41w832ta3
11. Uk-116,044-04
12. (r)-3-((1-methyl-2-pyrrolidinyl)methyl)-5-(2-(phenylsulfonyl)ethyl)-1h-indole Monohydrobromide
13. 5-[2-(benzenesulfonyl)ethyl]-3-[[(2r)-1-methylpyrrolidin-2-yl]methyl]-1h-indole;hydrobromide
14. Nsc-759258
15. 3-(((r)-1-methyl-2-pyrrolidinyl)methyl)-5-(2-(phenylsulfonyl)ethyl)indole, Monohydrobromide
16. 5-[2-(phenylsulfonyl)ethyl]-3-[(2r)-pyrrolidin-2-ylmethyl]-1h-indole Hydrobromide
17. C22h26n2o2s.hbr
18. Unii-m41w832ta3
19. Relpax (tn)
20. Schembl317370
21. Chembl1201003
22. Dtxsid001016113
23. Hy-a0010
24. Eletriptan Hydrobromide (jan/usan)
25. Eletriptan Hydrobromide [mi]
26. Tox21_500408
27. Eletriptan Hydrobromide [jan]
28. Mfcd08141806
29. S3180
30. Akos024262728
31. Ac-3398
32. Bcp9000640
33. Ccg-221712
34. Cs-0379
35. Eletriptan Hydrobromide [mart.]
36. Nsc 759258
37. 3-[[(2r)-1-methyl-2-pyrrolidinyl]methyl]-5-[2-(phenylsulfonyl)ethyl]-1h-indole Hydrobromide
38. Eletriptan Hydrobromide [usp-rs]
39. Eletriptan Hydrobromide [who-dd]
40. Ncgc00261093-01
41. Bs-42146
42. Eletriptan Hydrobromide, >=98% (hplc)
43. Eletriptan Hydrobromide [orange Book]
44. Sw220149-1
45. D01973
46. J-011323
47. J-520433
48. Q27130865
49. 3-(n-methyl-2(r)-pyrrolidinyl Methyl)-5-[2-(phenyl Sulfonyl)ethyl]-1h-indole Hydrobromide
50. 3-(n-methyl-2(r)-pyrrolidinylmethyl)-5-(2-phenylsulphonylethly)-1h-indole Hydrobromide
51. 3-(n-methyl-2(r)-pyrrolidinylmethyl)-5-(2-phenylsulphonylethyl)-1h-indole Hydrobromide
52. 3-(n-methyl-2(r)-pyrrolidinylmethyl)-5-[2-(phenyl Sulfonyl)ethyl]-1h-indole Hydrobromide
53. 3-{[1-methylpyrrolidin-2(r)-yl]methyl}-5-(2-phenylsulphonylethyl)-1h-indole Hydrobromide
54. (r)-3-[(1-methyl-2-pyrrolidinyl) Methyl]-5-[2-(phenylsulfonyl) Ethyl]-1h-indole Monohydrobromide
55. 1h-indole, 3-(((2r)-1-methyl-2-pyrrolidinyl))methyl)-5-(2-(phenylsulfonyl)ethyl)-, Monohydrobromide
56. 1h-indole, 3-[[(2r)-1-methyl-2-pyrrolidinyl]methyl]-5-[2-(phenylsulfonyl)ethyl]-, Hydrobromide (1:1)
57. 3-[[(2r)-1-methyl-2-pyrrolidinyl]me Thyl]-5-[2-(phenylsulfonyl)ethyl]-1h-indole Hydrobromide
58. 5-[2-(benzenesulfonyl)ethyl]-3-[[(2r)-1-methylpyrrolidin-2-yl]methyl]-1h-indol-1-ium;bromide
| Molecular Weight | 463.4 g/mol |
|---|---|
| Molecular Formula | C22H27BrN2O2S |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 3 |
| Rotatable Bond Count | 6 |
| Exact Mass | 462.09766 g/mol |
| Monoisotopic Mass | 462.09766 g/mol |
| Topological Polar Surface Area | 61.6 Ų |
| Heavy Atom Count | 28 |
| Formal Charge | 0 |
| Complexity | 582 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
| 1 of 2 | |
|---|---|
| Drug Name | Eletriptan hydrobromide |
| Drug Label | RELPAX (eletriptan) Tablets contain eletriptan hydrobromide, which is a selective 5-hydroxytryptamine 1B/1D (5-HT1B/1D) receptor agonist. Eletriptan is chemically designated as (R)-3-[(1-Methyl-2-pyrrolidinyl)methyl]-5-[2-(phenylsulfonyl)ethyl]-1H-... |
| Active Ingredient | Eletriptan hydrobromide |
| Dosage Form | Tablet |
| Route | oral |
| Strength | eq 40mg base; eq 20mg base; 40mg; 20mg |
| Market Status | Tentative Approval |
| Company | Apotex; Teva Pharms Usa |
| 2 of 2 | |
|---|---|
| Drug Name | Eletriptan hydrobromide |
| Drug Label | RELPAX (eletriptan) Tablets contain eletriptan hydrobromide, which is a selective 5-hydroxytryptamine 1B/1D (5-HT1B/1D) receptor agonist. Eletriptan is chemically designated as (R)-3-[(1-Methyl-2-pyrrolidinyl)methyl]-5-[2-(phenylsulfonyl)ethyl]-1H-... |
| Active Ingredient | Eletriptan hydrobromide |
| Dosage Form | Tablet |
| Route | oral |
| Strength | eq 40mg base; eq 20mg base; 40mg; 20mg |
| Market Status | Tentative Approval |
| Company | Apotex; Teva Pharms Usa |
Serotonin Receptor Agonists
Endogenous compounds and drugs that bind to and activate SEROTONIN RECEPTORS. Many serotonin receptor agonists are used as ANTIDEPRESSANTS; ANXIOLYTICS; and in the treatment of MIGRAINE DISORDERS. (See all compounds classified as Serotonin Receptor Agonists.)
Registration Number : 304MF10075
Registrant's Address : Area Industrial del Llobregat, C/Argent 1,08755 Castellbisbal Barcelona SPAIN
Initial Date of Registration : 2022-05-18
Latest Date of Registration :
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 22912
Submission : 2009-06-29
Status : Active
Type : II
Date of Issue : 2025-04-24
Valid Till : 2028-05-25
Written Confirmation Number : WC-0002
Address of the Firm :
NDC Package Code : 15894-0031
Start Marketing Date : 2016-05-26
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (100kg/100kg)
Marketing Category : BULK INGREDIENT
| Available Reg Filing : CA |
Registration Number : 229MF10147
Registrant's Address : Area Industrial del Llobregat, C/Argent 1,08755 Castellbisbal Barcelona SPAIN
Initial Date of Registration : 2017-07-31
Latest Date of Registration :
GDUFA
DMF Review : Reviewed
Rev. Date : 2016-02-10
Pay. Date : 2015-09-25
DMF Number : 29616
Submission : 2015-09-24
Status : Active
Type : II
NDC Package Code : 63126-904
Start Marketing Date : 2015-09-24
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

GDUFA
DMF Review : Reviewed
Rev. Date : 2013-07-12
Pay. Date : 2012-12-14
DMF Number : 26099
Submission : 2012-05-30
Status : Active
Type : II
Registration Number : 306MF10042
Registrant's Address : 7-2-A2, Hetero Corporate, Industrial Estates, Sanath Nagar, Hyderabad-500 018, Telangana, INDIA
Initial Date of Registration : 2024-03-13
Latest Date of Registration :
Date of Issue : 2022-09-30
Valid Till : 2025-08-08
Written Confirmation Number : WC-0066
Address of the Firm :
NDC Package Code : 65977-0059
Start Marketing Date : 2002-12-26
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

GDUFA
DMF Review : Reviewed
Rev. Date : 2013-12-18
Pay. Date : 2013-10-25
DMF Number : 24528
Submission : 2010-12-29
Status : Active
Type : II
NDC Package Code : 48087-0102
Start Marketing Date : 2012-10-27
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 42128
Submission : 2025-07-21
Status : Active
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 30338
Submission : 2016-03-15
Status : Active
Type : II

GDUFA
DMF Review : Reviewed
Rev. Date : 2013-04-20
Pay. Date : 2012-11-07
DMF Number : 24504
Submission : 2010-12-28
Status : Active
Type : II
Registration Number : 229MF10075
Registrant's Address : Plot No. 14, 99 and 100, IDA, Pashamylaram Phase-II, Patancheru, Sangareddy District - 502307, Telangana, India
Initial Date of Registration : 2017-04-07
Latest Date of Registration :

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 22912
Submission : 2009-06-29
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 23651
Submission : 2010-03-25
Status : Inactive
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2017-02-28
Pay. Date : 2017-01-19
DMF Number : 31336
Submission : 2017-01-21
Status : Active
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2013-12-18
Pay. Date : 2013-10-25
DMF Number : 24528
Submission : 2010-12-29
Status : Active
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2013-07-12
Pay. Date : 2012-12-14
DMF Number : 26099
Submission : 2012-05-30
Status : Active
Type : II

GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 30338
Submission : 2016-03-15
Status : Active
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2013-04-20
Pay. Date : 2012-11-07
DMF Number : 24504
Submission : 2010-12-28
Status : Active
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2026-05-05
Pay. Date : 2026-04-08
DMF Number : 25076
Submission : 2011-06-27
Status : Active
Type : II

GDUFA
DMF Review : Complete
Rev. Date : 2016-02-10
Pay. Date : 2015-09-25
DMF Number : 29616
Submission : 2015-09-24
Status : Active
Type : II

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Registration Number : 304MF10075
Registrant's Address : Area Industrial del Llobregat, C/Argent 1,08755 Castellbisbal Barcelona SPAIN
Initial Date of Registration : 2022-05-18
Latest Date of Registration : 2022-05-18
Registration Number : 229MF10147
Registrant's Address : Area Industrial del Llobregat, C/Argent 1,08755 Castellbisbal Barcelona SPAIN
Initial Date of Registration : 2017-07-31
Latest Date of Registration : 2017-07-31
Eletriptan hydrobromide "Apitoria"
Registration Number : 306MF10085
Registrant's Address : Plot No. 2, Maitrivihar, Ameerpet, Hyderabad, Telangana, INDIA.
Initial Date of Registration : 2024-07-03
Latest Date of Registration : 2024-07-03

Registration Number : 229MF10175
Registrant's Address : Plot No. 2, Maitrivihar, Ameerpet, Hyderabad Telangana, India
Initial Date of Registration : 2017-09-04
Latest Date of Registration : 2017-09-04

Registration Number : 306MF10042
Registrant's Address : 7-2-A2, Hetero Corporate, Industrial Estates, Sanath Nagar, Hyderabad-500 018, Telang...
Initial Date of Registration : 2024-03-13
Latest Date of Registration : 2024-03-13

Registration Number : 229MF10075
Registrant's Address : Plot No. 14, 99 and 100, IDA, Pashamylaram Phase-II, Patancheru, Sangareddy District ...
Initial Date of Registration : 2017-04-07
Latest Date of Registration : 2017-04-07

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.
Date of Issue : 2025-04-24
Valid Till : 2028-05-25
Written Confirmation Number : WC-0002
Address of the Firm : Plot No. A-2, A-2/1, A-2/2, UPSIDC Industrial Area, Bijnor Road, Gajraula -24423...
Date of Issue : 2025-08-08
Valid Till : 2028-06-10
Written Confirmation Number : WC-0017
Address of the Firm : Unit-II, SurveyNo.:10&13,Gaddapotharam (Village), IDA-Kazipally, Jinnaram (Manda...

Date of Issue : 2022-09-30
Valid Till : 2025-08-08
Written Confirmation Number : WC-0066
Address of the Firm : Plot No 1, Hetero Infrastructure SEZ Ltd., N. Narasapuram, Anakapalli -531081, A...

Eletriptan Hydrobromide Monohydrate IH
Date of Issue : 2024-01-15
Valid Till : 2027-01-14
Written Confirmation Number : WC-0577
Address of the Firm : Unit-lll, Sy.No.145/A, 145/AA & 147, Ramalingampally Village, Bommalaramaram, Ma...

Date of Issue : 2025-09-29
Valid Till : 2028-09-28
Written Confirmation Number : WC-0118
Address of the Firm : Unit-1, Survey No. 10, Gaddapotharam (V), Kazipally Industrial Area, Jinnaram (M...

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Registrant Name : Pfizer Korea
Registration Date : 2011-12-09
Registration Number : Su189-14-ND
Manufacturer Name : Pfizer Ireland Pharmaceutica...
Manufacturer Address : Ringaskiddy Active Pharmaceutical Ingredient Plant, PO Box 140, Ringaskiddy, Co. Cork...

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Eletriptan HBr is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Spinal Cord Injuries.
Lead Product(s): Eletriptan Hydrobromide,Inapplicable
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Miscellaneous
Sponsor: VectorB2B
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 06, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Eletriptan Hydrobromide,Inapplicable
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : VectorB2B
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Eletriptan HBr is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Spinal Cord Injuries.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 06, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Eletriptan is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Migraine Disorders.
Lead Product(s): Eletriptan Hydrobromide,Inapplicable
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 21, 2013

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Eletriptan Hydrobromide,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Eletriptan is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Migraine Disorders.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 21, 2013

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Eletriptan is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Migraine Disorders.
Lead Product(s): Eletriptan Hydrobromide,Inapplicable
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 18, 2013

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Eletriptan Hydrobromide,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Eletriptan vs Sumatriptan: A Double-blind, Placebo-controlled, Multiple Migraine Attack Study
Details : Eletriptan is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Migraine Disorders.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 18, 2013

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Eletriptan is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Migraine Disorders.
Lead Product(s): Eletriptan Hydrobromide,Inapplicable
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 18, 2013

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Eletriptan Hydrobromide,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Comparative Study of Oral Eletriptan (40mg and 80mg), Oral Sumatriptan (25mg and 50mg) and Placebo
Details : Eletriptan is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Migraine Disorders.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 18, 2013

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Eletriptan is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Migraine Disorders.
Lead Product(s): Eletriptan Hydrobromide,Inapplicable
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 07, 2013

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Eletriptan Hydrobromide,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy, Safety, and Tolerability of Oral Eletriptan for Treatment of Acute Migraine
Details : Eletriptan is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Migraine Disorders.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 07, 2013

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Eletriptan HBr is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Migraine without Aura.
Lead Product(s): Eletriptan Hydrobromide,Inapplicable
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 22, 2013

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Eletriptan Hydrobromide,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Eletriptan Provides Consistent Migraine Relief: Results Of A Within-Patient Multiple-Dose Study
Details : Eletriptan HBr is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Migraine without Aura.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 22, 2013

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Eletriptan is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Lead Product(s): Eletriptan Hydrobromide,Inapplicable
Therapeutic Area: Undisclosed Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 08, 2010

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Eletriptan Hydrobromide,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Eletriptan Pharmacokinetics In Korean Males
Details : Eletriptan is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 08, 2010

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]CAS Number : 6404-31-5
End Use API : Eletriptan Hydrobromide
About The Company : Blue Jet Healthcare is a global, science-driven pharmaceutical company specializing in collaboration, development, and manufacturing of advanced pharmaceutical ...

(R)-5-Bromo-3-((1-methyl-2-pyrrolidinyl)methyl]-1H...
CAS Number : 143322-57-0
End Use API : Eletriptan Hydrobromide
About The Company : TEXLAB INDUSTRIES was established in 1971, manufacturing & trading related business. TEXLAB INDUSTRIES - company launched by Late Shree AMBALAL MISTRY for local...

CAS Number : 5535-48-8
End Use API : Eletriptan Hydrobromide
About The Company : Founded in 1986, Kekule has developed from a manufacturer of few molecules to a preferred vendor for many complex molecules requiring multistage synthesis. Work...

CAS Number : 6163-58-2
End Use API : Eletriptan Hydrobromide
About The Company : Sanpra Synthesis strongly believes that with its expertise and innovative pharmaceutical business background, it is aptly positioned for APIs and intermediates ...

5-Bromo-3-(((R)-1-methylpyrrolidin-2-yl) methyl)-1...
CAS Number : 143322-57-0
End Use API : Eletriptan Hydrobromide
About The Company : SMS Lifesciences is a global player in APIs/Intermediates manufacturing having a strong research and manufacturing team supported by state of the art facilities...

CAS Number : 5535-48-8
End Use API : Eletriptan Hydrobromide
About The Company : SMS Lifesciences is a global player in APIs/Intermediates manufacturing having a strong research and manufacturing team supported by state of the art facilities...

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ANALYTICAL
ABOUT THIS PAGE
95
PharmaCompass offers a list of Eletriptan Hydrobromide API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Eletriptan Hydrobromide manufacturer or Eletriptan Hydrobromide supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Eletriptan Hydrobromide manufacturer or Eletriptan Hydrobromide supplier.
A Eletriptan Hydrobromide manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Eletriptan Hydrobromide, including repackagers and relabelers. The FDA regulates Eletriptan Hydrobromide manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Eletriptan Hydrobromide API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Eletriptan Hydrobromide manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.
A Eletriptan Hydrobromide supplier is an individual or a company that provides Eletriptan Hydrobromide active pharmaceutical ingredient (API) or Eletriptan Hydrobromide finished formulations upon request. The Eletriptan Hydrobromide suppliers may include Eletriptan Hydrobromide API manufacturers, exporters, distributors and traders.
click here to find a list of Eletriptan Hydrobromide suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.
A Eletriptan Hydrobromide DMF (Drug Master File) is a document detailing the whole manufacturing process of Eletriptan Hydrobromide active pharmaceutical ingredient (API) in detail. Different forms of Eletriptan Hydrobromide DMFs exist exist since differing nations have different regulations, such as Eletriptan Hydrobromide USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Eletriptan Hydrobromide DMF submitted to regulatory agencies in the US is known as a USDMF. Eletriptan Hydrobromide USDMF includes data on Eletriptan Hydrobromide's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Eletriptan Hydrobromide USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Eletriptan Hydrobromide suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Eletriptan Hydrobromide Drug Master File in Japan (Eletriptan Hydrobromide JDMF) empowers Eletriptan Hydrobromide API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Eletriptan Hydrobromide JDMF during the approval evaluation for pharmaceutical products. At the time of Eletriptan Hydrobromide JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Eletriptan Hydrobromide suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Eletriptan Hydrobromide Drug Master File in Korea (Eletriptan Hydrobromide KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Eletriptan Hydrobromide. The MFDS reviews the Eletriptan Hydrobromide KDMF as part of the drug registration process and uses the information provided in the Eletriptan Hydrobromide KDMF to evaluate the safety and efficacy of the drug.
After submitting a Eletriptan Hydrobromide KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Eletriptan Hydrobromide API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Eletriptan Hydrobromide suppliers with KDMF on PharmaCompass.
A Eletriptan Hydrobromide written confirmation (Eletriptan Hydrobromide WC) is an official document issued by a regulatory agency to a Eletriptan Hydrobromide manufacturer, verifying that the manufacturing facility of a Eletriptan Hydrobromide active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Eletriptan Hydrobromide APIs or Eletriptan Hydrobromide finished pharmaceutical products to another nation, regulatory agencies frequently require a Eletriptan Hydrobromide WC (written confirmation) as part of the regulatory process.
click here to find a list of Eletriptan Hydrobromide suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Eletriptan Hydrobromide as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Eletriptan Hydrobromide API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Eletriptan Hydrobromide as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Eletriptan Hydrobromide and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Eletriptan Hydrobromide NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Eletriptan Hydrobromide suppliers with NDC on PharmaCompass.
Eletriptan Hydrobromide Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Eletriptan Hydrobromide GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Eletriptan Hydrobromide GMP manufacturer or Eletriptan Hydrobromide GMP API supplier for your needs.
A Eletriptan Hydrobromide CoA (Certificate of Analysis) is a formal document that attests to Eletriptan Hydrobromide's compliance with Eletriptan Hydrobromide specifications and serves as a tool for batch-level quality control.
Eletriptan Hydrobromide CoA mostly includes findings from lab analyses of a specific batch. For each Eletriptan Hydrobromide CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Eletriptan Hydrobromide may be tested according to a variety of international standards, such as European Pharmacopoeia (Eletriptan Hydrobromide EP), Eletriptan Hydrobromide JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Eletriptan Hydrobromide USP).